Pharmaceuticals, Biotechnology and Life Sciences
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–#Clinicaltrials–Please note the Hope Biosciences boilerplate has been updated. The corrected release reads: VIRTRIAL AWARDED FDA-APPROVED DECENTRALIZED CLINICAL…
The trial, which received a $4.1 million in grants from the National Institutes of Health and Gateway for Cancer Research,…
Shionogi has reported positive Results from Cefiderocol Phase III study in adults with nosocomial pneumonia caused by gram-negative pathogens, as cefiderocol met primary endpoint of non-inferiority in 14-day all-cause mortality compared to high-dose meropenem.
Novartis has received FDA approval for Beovu, the only anti-VEGF in wet AMD recommended to maintain eligible patients on up to three-month dosing intervals immediately after the loading phase with no compromise in efficacy, for AMD patients, which are in risk from causes blindness and loss of independence.
Merck has issued its corporate responsibility report, illustrating its approach to long-Term sustainability for business and society.
NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to…
AAO 2019 To Feature Multiple Presentations by Leading Experts on Allegro’s Dry Age-Related Macular Degeneration and Dry Eye Disease Assets…
DUBLIN–(BUSINESS WIRE)–Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon…
Biom’up SA, a specialist in surgical hemostasis, announces its flagship product, HEMOBLAST Bellows, has been approved for open as well as laparoscopic surgery by the Australian TGA regulatory authority for commercialization in the sizeable and growing Australian market.
Kodiak Sciences will present emerging data from the Phase 1b clinical study of KSI-301 in treatment-naïve patients with neovascular age-related macular degeneration (wet AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO) in San Francisco, in an upcoming event, at the Annual Meeting of the American Academy of Ophthalmology (AAO).